GL
ALXN

GLG LLC’s Alexion Pharmaceuticals ALXN Stock Holding History

GLG LLC’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$7.67M Buy
64,133
+25,000
+64% +$3.04M 0.55% 50
2017
Q3 		$5.49M Sell
39,133
-3,639
-9% -$494K 0.36% 77
2017
Q2 		$5.2M Sell
42,772
-4,971
-10% -$579K 0.32% 89
2017
Q1 		$5.79M Buy
47,743
+25,260
+112% +$3.26M 0.32% 88
2016
Q4 		$2.75M Sell
22,483
-33,527
-60% -$4.1M 0.19% 130
2016
Q3 		$6.86M Buy
56,010
+12,162
+28% +$1.57M 0.49% 56
2016
Q2 		$5.12M Buy
43,848
+26,929
+159% +$3.82M 0.39% 76
2016
Q1 		$2.35M Sell
16,919
-2,557
-13% -$375K 0.15% 181
2015
Q4 		$3.71M Sell
19,476
-24,140
-55% -$4.22M 0.22% 125
2015
Q3 		$6.82M Buy
43,616
+30,365
+229% +$5.54M 0.17% 144
2015
Q2 		$2.4M Sell
13,251
-3,709
-22% -$640K 0.05% 330
2015
Q1 		$2.94M Buy
+16,960
New +$3.07M 0.08% 268
2014
Q3 		– Sell
-23,062
Closed -$3.6M – 712
2014
Q2 		$3.6M Buy
23,062
+9,990
+76% +$1.58M 0.11% 254
2014
Q1 		$1.99M Buy
+13,072
New +$2.08M 0.07% 321

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GLG LLC's ALXN Position: Q4 2017 in Review

GLG LLC increased its Alexion Pharmaceuticals (ALXN) stake by 64% in Q4 2017, buying an estimated $3.04M and bringing the position to 64,133 shares worth $7.67M. The position accounts for 0.55% of the portfolio, ranked #50.

GLG LLC first reported a position in ALXN in Q1 2014 and has held it in 14 quarters since. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

  • GLG LLC held 64,133 shares of Alexion Pharmaceuticals worth $7.67M as of Q4 2017.
  • GLG LLC bought 25,000 Alexion Pharmaceuticals shares in Q4 2017, an estimated $3.04M.
  • Alexion Pharmaceuticals made up 0.55% of GLG LLC's portfolio in Q4 2017, its #50 holding.
  • GLG LLC first reported a position in Alexion Pharmaceuticals in Q1 2014 and has held it in 14 quarters since.
  • 587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on GLG LLC's 13F filing for Q4 2017, filed 14 Feb 2018.